WSAAI 2019: 57th Annual Scientific Session

Maui, HI US
January 20, 2019 to January 24, 2019

There is a need for clinicians to stay advanced in their practice on diagnostic strategies and newer treatments of allergic disease. Lectures based on the latest clinical evidence as well as incorporating  AAAAI/ACAAI practice parameters, will allow clinicians to avoid negative consequences as they pertain to patient care --- these include: under treatment, inappropriate use of diagnostic tests and lack of clinical awareness.  The WSAAI 2019 meeting will provide up to date diagnostic strategies and treatments in the areas of Food Allergy, Atopic Dermatitis, Primary Immunodeficiency, HAE, Asthma and CRS.
 

Accreditation
This 
activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Western Society of Allergy, Asthma & Immunology (WSAAI).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The 
American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  20 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by independent educational grants from Aimmune, CSL Behring, Grifols, Optinose, Pharming, Sanofi, Shire and Stallergenes Greer

 

Target Audience

Practicing allergists
Allied health professionals

 

Learning Objectives

At the conclusion of this meeting, learners should be able to:

1.  Evaluate current therapeutic interventions and adapt evidence-based diagnostic strategies in the treatment of HAE.
2.  Summarize current practice parameters and summarize current research data in the diagnosis, treatment and potential primary prevention of food allergy.
3.  Synthesize expert opinion and clinical research data in applying the latest diagnostic and treatment strategies for Chronic Rhinosinusitis.
4.  Investigate the immunologic and microbial mechanisms of Atopic Dermatitis and incorporate emerging bacteriologic and immunomodulatory treatment strategies for patients with AD.
5.   Recommend an evidence-based, personalized approach for immunoglobulin replacement therapy in managing patients with PIDD.
6.  Manage optimal treatment strategies for asthma and other allergic diseases during pregnancy
7.  Summarize the mechanisms by which pollutants impart airway disease and recommend areas of potential intervention.

Additional information
Disclosure: 

WSAAI 2019: 57th Annual Scientific Session

Maui, Hawaii | January 20-24, 2019

 

Disclosure Policy                                                                                                                                 

 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months.  All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations.  It is required that disclosure be provided to the learners prior to the start of the activity.  Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist.  Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.  Disclosure in no way implies that the information presented is biased or of lesser quality.  It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.  Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

 

The individuals listed below disclose the following financial relationships:

 

Noam A. Cohen MD, PhD – Speaker

Investigator – Pershing Square Foundation, RLG Foudnation

Consultant – GSK/Novartis, Bayer Health

Peer review competitive research – NIDCD

Founding Partner – 4 Sinuses LLC

Research – GeneOne Life Sciences

 

Richard L. Gallo MD, PhD – Speaker

Consultant – MatriSys Bioscience, Sente Inc.

Co-founder – MatriSys Bioscience

Independent Contractor – Regeneron

 

Jordan Orange, MD, PhD – Speaker

Consultant – Shire, CSL Behring

Speaker – Shire

Advisory Board Member – ADMA

Author - UptoDate

 

Michael Schatz, MD, MS – Speaker

Research grant – Merck, GlaxoSmithKline, AstraZeneca

 

Katharine M. Woessner, MD – Speaker

Speaker – Shire, Teva

Advisory Board Member - Shire

 

 

Bruce Zuraw, MD – Speaker

Consultant – CSL Behring, Shire, Adverum, Biocryst, Novartis

 

Jennifer Namazy, MD – Planner, Moderator, Reviewer

Advisory Board – Genentech; Consultant – GlaxoSmithKline

 

Warner Carr, MD – Planner, Moderator

Consultant – AstraZeneca, Boehringer Ingelheim, Meda, Regeneron, Sanofi, Teva; Speaker – AstraZeneca, Boehringer Ingelheim, Regeneron, Sanofi, Teva

 

Travis Miller, MD – Planner, Moderator

Advisor – Aimmune, Boston Scientific, Credit Suisse, DBV, Kaleo, Genentech, Optinose, Teva; Speaker – ALK, AstraZeneca, Genentech

 

Andrew White, MD – Planner

Speaker – AstraZeneca; Advisory Board Member – AstraZeneca

 

The following have no relevant financial relationships to disclose:

Catherine Lozupone, PhD – Speaker

David B. Peden, MD, MS – Speaker

Scott H. Sicherer, MD – Speaker

Donata Vercelli, MD – Speaker

Matthew Bowdish, MD – Planner, Moderator

Karol Anderson – Planner

Rene Anderson-Cowell, MD – Planner

David Elkayam, MD – Planner

Steve Machtinger, MD – Planner

Course summary
Available credit: 
  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
Course opens: 
01/20/2019
Course expires: 
01/24/2021
Event starts: 
01/20/2019 - 3:00pm
Event ends: 
01/24/2019 - 5:30pm
Cost:
$0.00
Rating: 
0
Fairmont Kea Lani
4100 Wailea Alanui Drive
Maui, HI 96753
United States

Accreditation
This 
activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Western Society of Allergy, Asthma & Immunology (WSAAI).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The 
American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  20 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance

Accreditation Period

Course opens: 
01/20/2019
Course expires: 
01/24/2021

Price

Cost:
$0.00
Please login or create an account to take this course.